Mirum Pharmaceuticals, Inc.
Clinical trials sponsored by Mirum Pharmaceuticals, Inc., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug could soothe unbearable itch in rare liver conditions Results expected Oct 2026 (estimated)
- New pill aims to stop the relentless itch of a rare liver disease Results expected Jan 2027 (estimated)
- New hope for hepatitis delta: phase 3 trial launches Results expected Jun 2027 (estimated)
- New hope for hepatitis delta: can switching drugs clear the virus? Results expected Aug 2027 (estimated)
-
New hope for hepatitis delta: can switching drugs clear the virus?
Disease control Recruiting nowThis study tests whether switching from the current drug bulevirtide to a new drug called brelovitug can better control chronic hepatitis Delta. About 120 adults who have been on bulevirtide for at least 6 months will take brelovitug for 24 weeks. The main goal is to see if the v…
Phase 2/3 • Sponsor: Mirum Pharmaceuticals, Inc. • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New hope for hepatitis delta: phase 3 trial launches
Disease control Recruiting nowThis phase 3 trial compares a new drug, brelovitug, to an existing treatment (bulevirtide) for chronic hepatitis delta, a serious liver infection. About 172 adults with the infection will receive either drug to see which better controls the virus and normalizes liver enzymes. The…
Phase 3 • Sponsor: Mirum Pharmaceuticals, Inc. • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
New drug livmarli tracked for Long-Term safety in kids with rare liver disorders
Disease control Recruiting nowThis study follows 230 children with Alagille syndrome or progressive familial intrahepatic cholestasis (PFIC) who are taking Livmarli, a drug to reduce bile buildup and itching. Researchers will monitor side effects, liver function, and long-term outcomes like need for transplan…
Phase 4 • Sponsor: Mirum Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug trial hopes to ease fragile x symptoms in boys and men
Symptom relief Recruiting nowThis study tests an experimental drug called MRM-3379 in males aged 13 to 45 with Fragile X Syndrome. The goal is to see if the drug is safe and can improve symptoms like learning and behavior. Participants will take the drug or a placebo for 12 weeks. The study is currently recr…
Phase 2 • Sponsor: Mirum Pharmaceuticals, Inc. • Aim: Symptom relief
Last updated Aug 26, 2026 00:00 UTC
-
Tracing a new Drug's journey through the body
Knowledge-focused Recruiting nowThis early-stage trial tracks how the experimental drug MRM-3379 moves through the body and is eliminated. Eight healthy men receive a single oral dose of a specially labeled version of the drug. Researchers measure radioactivity in blood, urine, and feces to understand absorptio…
Phase 1 • Sponsor: Mirum Pharmaceuticals, Inc. • Aim: Knowledge-focused
Last updated Jul 19, 2026 00:00 UTC